Objective: This study intended to analyze the prognosis of patients with
stage IIIC squamous cervical cancer who underwent the Obstetrics and
Gynecology Hospital of Fudan University (FUOG) Treatment, and explored
the factors influencing their prognosis. Design: A retrospective study.
Setting: A large tertiary hospital specializing in obstetrics and
gynecology in China. Population or Sample: This study collected data
from 717 patients with stage IIIC squamous cervical cancer who underwent
FUOG Treatment in our hospital from January 2016 to December 2020.
Methods: Kaplan-Meier method was used to estimate progression-free
survival (PFS) and overall survival (OS). Stratified analysis was
performed to examine the risk factors. Main Outcome Measures: The main
outcomes were 3-year PFS and OS. Results: The 3-year OS was 90.9% for
patients with stage IIIC squamous cervical cancer, 91.5% for stage
IIIC1 and 83.2% for stage IIIC2, respectively. The 3-year PFS was
84.8%, 85.3% for stage IIIC1 and 78.8% for stage IIIC2, respectively.
Undifferentiated squamous carcinoma was an independent prognostic factor
for OS (HR: 5.793, p=0.0064) and PFS (HR: 4.663, p=0.0033).
Postoperative patients with standard adjuvant therapy had better 3-year
OS outcomes than patients with non-standard therapy (88.4% vs 73.4%,
p=0.007). Patients with undifferentiated type (OR=8.471), positive
parietal infiltration (OR=3.339), or tumor infiltration depth of 1/3-2/3
(OR=5.454) were more likely to have distant recurrence. Conclusions: The
prognosis of patients with stage IIIC cervical squamous carcinoma
treated with the FUOG Treatment is satisfactory. However, risk factors
such as undifferentiated type, positive paracervical infiltration, and
non-standard adjuvant therapy can negatively affect prognosis.